MedTrace Logo

Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or Type 2 Diabetes

NCT01467323 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 303

Last updated 2017-01-04

No results posted yet for this study

Summary

This trial is conducted in Europe. The aim of this trial is to evaluate the efficacy and safety of biphasic insulin aspart 30 in subjects with type 1 or type 2 diabetes.

Conditions

  • Diabetes
  • Diabetes Mellitus, Type 1
  • Diabetes Mellitus, Type 2

Interventions

DRUG

biphasic insulin aspart

Injected subcutaneously (under the skin) twice daily

DRUG

biphasic human insulin

Injected subcutaneously (under the skin) twice daily

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR,1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-04-30
Primary Completion
1998-09-30
Completion
1998-09-30

Countries

  • Austria
  • Germany
  • Ireland
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01467323 on ClinicalTrials.gov